Skip to main content

Advertisement

Table 2 Characteristics of individual patients

From: Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

No-TACE
Patient Number Age Gender Etiology AFP # Tumors at Dx Size (cm) pre-op Within Milan Growth rate (cm/mo.) Largest tumor dia by path Days to Transplant* Recur Time to Recur Reasons not to TACE
A B C D E
N1 62 F HCV 20 2 1.9, 1.6 Y N/A 1.6 49 N N/A X     
N2 48 M HCV 13 1 1.9 Y N/A 2 340 N N/A X     
N3 49 F HCV 1207 3 1.3, 2.0, 2.5 Y N/A 3.4 188 N N/A X     
N4 52 F HCV 107 2 1.0, 2.1 Y N/A 2.3 160 N N/A X     
N5 65 M HCV 5.3 2 N/A N/A N/A 1.1 12 N N/A     X  
N6 56 M HBV 4 1 4.8 Y N/A 3.5 59 N N/A X     
N7 68 M HCV 1327 2 1.4, 2.6 Y 0.12 2.8 205 N N/A      X
N8 46 F HCV 2809 1 3.8 Y 0.2 6 115 N N/A X   X   
N9 48 M HCV 686 1 3 Y 0.4 3.6 116 N N/A X     
N10 53 M HCV 3 1 1.5 Y 0.1 2.5 190 N N/A X     
N11 45 M HCV 4 1 5.4 N N/A 5.1 45 N N/A   X    
N12 57 M HCV 6 1 2.8 Y N/A 4 41 Y 24mo. X     
N13 55 M HCV 11 2 0.9, 1.6 Y N/A 2.3 38 N N/A X     
N14 49 M HCV 7 1 5.3 N N/A 5.5 87 N N/A   X    
N15 53 M HCV 2461 1 2.8 Y N/A 5 95 N N/A X     
N16 55 M HCV 7 2 1.0, 0.8 Y N/A 1 0 N N/A     X  
N17 52 M HCV 18 1 2.5 Y N/A 3.1 128 N N/A X   X   
N18 56 F HCV 19 1 3.3 Y N/A 3.5 117 N N/A X   X   
N19 68 M HCV 9 2 2.2, 1.6 Y 0 2 377 N N/A X   X   
N20 56 M HCV 7 1 N/A N/A N/A 1 0 N N/A     X  
N21 53 M PSC 40 2 N/A N/A N/A 0.3 0 N N/A     X  
N22 64 M HCV 20 1 2.1 Y N/A 3.5 179 N N/A X     
N23 49 M HCV 3.6 1 N/A N/A N/A 1.5 0 N N/A     X  
  1. A = Patient was within Milan.
  2. B = Outside Milan but eligible for transplant by MELD with a short waiting time expected.
  3. C = Patient could not tolerate procedure.
  4. D = Tumor not appreciated pre-op.
  5. E = Procedure planned, not able to perform prior to transplant.
  6. * = Days from HCC diagnosis to transplant.